This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: The Only Data Point That Matters

NEW YORK (Real Money) -- Take a look at what worked in the fourth quarter. If you do, you can see why I write -- right up top in Get Rich Carefully -- that the only economic metric worth following is the payroll employment number that comes out on the first Friday of every month.

First, let me say: We are bombarded with numbers. We have all sorts of them -- purchasing managers reports; retail sales; new and used home sales; durable goods; consumer confidence; inflation, both producer and consumer; Federal Reserve minutes; and the index of home pricing.

I don't want to say, "Throw these away, they mean nothing." They can impact the pricing in U.S. Treasury bonds, at least ephemerally. They must be reported because they are, indeed, news. But for the most part they have no lasting impact, almost none whatsoever, at least when compared with that payroll report. This was the number that predicted the downturn, and it was the number that led to a wholesale shift in stock focus -- the big rotation -- in the fourth quarter. This was vital when it came to picking the right stocks that outperformed, and outperformed substantially, in the latter half of the year.

I know that might seem unfair to those who make a big deal of every number, but let's look at what happened in the fourth quarter.

Must Read: Jim Cramer: The Most Obvious of Years

First, as soon as the first good number showed up, investors started dumping everything that was soft goods or recession-related, including General Mills (GIS), Kellogg (K), Eli Lilly (LLY), Pfizer (PFE) and Johnson & Johnson (JNJ). It was almost as if these stocks caught the plague. If you had stayed with them or hadn't cut them back because you had wanted to be diversified -- something I wouldn't have blamed you one bit for -- your portfolio would have stopped increasing in value. It would have just hit a wall.

It is important to recognize that the same idea generally applied to the drugmakers. Unless there was a new breakthrough drug or approval -- as was the case with Gilead (GILD) and its hepatitis C drug, newly sanctioned by the Food and Drug Administration -- the same underperformance struck hard there, too after the big employment number. It just stopped this once-red-hot group in its tracks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs